verezdoВестник репродуктивного здоровьяBulletin of Reproductive Health2075-65692310-421XEndocrinology Research Centre (Moscow)10.14341/brh2009139-44verezdo-8549Research ArticleСтатьиArticlesМолочная железа как своеобразный интракринный органMolochnaya zheleza kak svoeobraznyy intrakrinnyy organСметникВ ПSmetnikV P-КоноваловаВ НKonovalovaV N-ФГУ Научный центр акушерства, гинекологии и перинатологии им. В.И. Кулакова Росмедтехнологий20091503200901№1 (2009)3944Copyright © Сметник В.П., Коновалова В.Н., 20092009Сметник В.П., Коновалова В.Н.Smetnik V.P., Konovalova V.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vrz-endojournals.ru/jour/article/view/8549

В статье рассмотрены особенности молочной железы как интракринного органа, представлены пути синтеза и метаболизма эстрогенов в ее ткани. Приведены эпидемиологические данные по заболеваемости раком молочных желез (РМЖ) на фоне заместительной гормональной терапии (ЗГТ), рассмотрены факторы риска его развития. Подробно представлены пути метаболизма эстрогенов и свойства их гидроксиметаболитов. Приведены данные собственных исследований по определению уровней основных гидроксиметаболитов эстрогенов у женщин в постменопаузе группы низкого риска развития РМЖ и не принимающие препараты ЗГТ, а также их взаимосвязь с основными факторами риска РМЖ.

молочная железаэстрогеныгидроксиметаболиты эстрогеновReferencesLabrie F. et al. Breast. In: A.R. Genazzani, F. Petralgia, P.G. Artini. Advances (ed). Gynecological Endocrinology. Parthenon Publishing Group 2004; 246.Labrie F. et al. Breast. In: A.R. Genazzani, F. Petralgia, P.G. Artini. Advances (ed). Gynecological Endocrinology. Parthenon Publishing Group 2004; 246.Key T.J. et al. Epidemiology of breast cancer. Lancet Oncol 2001; 2: 133–140.Key T.J. et al. Epidemiology of breast cancer. Lancet Oncol 2001; 2: 133–140.Lord R.S. et al. Estrogen metabolism and diet-cancer connection: rationale for assissing the ratio of urinary hydroxylated estrogen metabolites. Alternat Med Rev 2002; 7 (2): 112–129.Lord R.S. et al. Estrogen metabolism and diet-cancer connection: rationale for assissing the ratio of urinary hydroxylated estrogen metabolites. Alternat Med Rev 2002; 7 (2): 112–129.Reed M.J. Role of enzymes and tissue-specific actions in steroids. Maturitas 2004; 48 (1): 18–23.Reed M.J. Role of enzymes and tissue-specific actions in steroids. Maturitas 2004; 48 (1): 18–23.Bradlow H.L. et al. 2-Hydroxyestrone: the «good» estrogen. J Endocrinol 1996; 150: 259–265.Bradlow H.L. et al. 2-Hydroxyestrone: the «good» estrogen. J Endocrinol 1996; 150: 259–265.Meilahn E.N. et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998; 78: 1250–1255.Meilahn E.N. et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998; 78: 1250–1255.Muti P. et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alphahydroxyestrone ratio in premeno-pausal and postmenopausal women. Epidemiology 2000; 11: 635–640.Muti P. et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alphahydroxyestrone ratio in premeno-pausal and postmenopausal women. Epidemiology 2000; 11: 635–640.Coker A. et al. Ethnic differences in estrogen metabolism in healthy women. J Natl Cancer Inst 1997; 89: 89–90.Coker A. et al. Ethnic differences in estrogen metabolism in healthy women. J Natl Cancer Inst 1997; 89: 89–90.Riza E. et al. Urinary estrogen metabolites and mammographic parenchymal patterns in postmenopausal women. Cancer Epidemiol Biomark Prev 2001; 10: 627–634.Riza E. et al. Urinary estrogen metabolites and mammographic parenchymal patterns in postmenopausal women. Cancer Epidemiol Biomark Prev 2001; 10: 627–634.Ursin G. et al. Urinary 2-hydroxyestrone/16alphahydroxyestrone ratio and risk of breast can-cer in postmenopausal women. J Natl Cancer Inst 1999; 91: 1067–1072.Ursin G. et al. Urinary 2-hydroxyestrone/16alphahydroxyestrone ratio and risk of breast can-cer in postmenopausal women. J Natl Cancer Inst 1999; 91: 1067–1072.Bradlow H.L., Jernström H., Sepkovic D.W. et al. Comparison of plasma and urinary levels of 2-hydroxyestrogen and 16 alphahydroxyestrogen metabolites. Mol Genet Metab 2006; 87 (2): 135– 146.Bradlow H.L., Jernström H., Sepkovic D.W. et al. Comparison of plasma and urinary levels of 2-hydroxyestrogen and 16 alphahydroxyestrogen metabolites. Mol Genet Metab 2006; 87 (2): 135– 146.Atkinson C. et al. Effects of a moderate intensity exercise intervention on estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2002; 13: 868–874.Atkinson C. et al. Effects of a moderate intensity exercise intervention on estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2002; 13: 868–874.Fowke J.H. et al. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with preversus posttreatment collection. Steroids 2003; 68 (1): 65–72.Fowke J.H. et al. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with preversus posttreatment collection. Steroids 2003; 68 (1): 65–72.Reina C. et al. The oxidative metabolism of estrogen modulates response to ERT/HRT in postmenopausal women. Bone 2004; 35: 682–688.Reina C. et al. The oxidative metabolism of estrogen modulates response to ERT/HRT in postmenopausal women. Bone 2004; 35: 682–688.Wellejus A. et al. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev 2005; 14 (9): 2137–2142.Wellejus A. et al. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev 2005; 14 (9): 2137–2142.Kabat G.C. et al. Estrogen metabolism and breast cancer. Epidemiology 2006; 17 (1): 80–88.Kabat G.C. et al. Estrogen metabolism and breast cancer. Epidemiology 2006; 17 (1): 80–88.

The authors declare that there are no conflicts of interest present.